EpiVax, Inc. Tregitope Technology: a Paradigm Shift

Providence RI (Vocus/PRWEB ) March 2, 2010 -- EpiVax, a paradigm-shifting biotechnology company, takes the road this spring to share news about Tregitope – the small peptides contained in IgG that trigger regulatory T cells – and other cutting-edge science and technology with scientific colleagues. Starting in Asia, EpiVax will be presenting the Tregitope paradigm shift at 10 conferences between March and August 2010. A list of upcoming conferences is presented here below.

MORE ON THIS TOPIC